Paper Contents
Abstract
ABSTRACT Chronic Myeloid Leukaemia patients (CML) with presence of Breakpoint Cluster RegionAbelson (BCR-ABL) gene rearrangement t (9; 22) (q34; q11) predicts response to targeted therapy and survival. Hence, this study intends to explore clinical relevance of Major BCR-ABL fusion gene (MBCR-ABL) expression in CML patients and validate %NCN (Normalized copy number) with %IS-NCN (Normalized copy number on international scale). Fifty haematologically & cytogenetically confirmed CML patients were enrolled. Total RNA was extracted from blood samples and was reverse transcribed to cDNA followed by quantification of MBCR-ABL1 transcript by real time PCR. Statistical analysis was done by SPSS software. Fifty CML patients, included 15 untreated (UT) patients, 15 treatment non-responders (TNRs) and 20 treatment responders (TRs). MBCR-ABL1 expression decreased across groups, with TRs showing the lowest averages, suggesting progression towards major molecular response. CML patients with abnormal haematological parameters trended higher expression levels of MBCR-ABL1 across all groups. Combining MBCR-ABL1 fusion gene analysis with traditional and haematological assessments, enhances disease monitoring and more timely interventions towards improved outcomes in managing CML. Moreover, the %NCN correspond to the IS-NCN values of M-BCR-ABL fusion gene, hematological parameters and Lactate dehydrogenase (LDH) values, which are useful in diagnosis and monitoring treatment response and management of CML patients during follow up.
Copyright
Copyright © 2024 Dr. Toral Mandalia. This is an open access article distributed under the Creative Commons Attribution License.
